Apogee Therapeutics, Inc. (APGE) Form 8-K — Sep 3, 2026

$APGEForm 8-KItems 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01Filed Sep 3, 2026, 8:53 AM ET0001140361-26-035537Original filing

AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026, with Merger Sub Andor Merger Co. merging into Apogee, which survived as an indirect wholly owned subsidiary of AbbVie. The transaction carries a total equity value of approximately $10.9 billion, funded by AbbVie with a combination of cash on hand and debt. Each Apogee share was converted into the right to receive $135.11 per share in cash, while in-the-money options, RSUs, restricted stock awards, and warrants were cashed out on the same basis.

Key figures

Deal Value Usd: 10900000000
Total equity value: approximately $10.9 billion
Merger agreement date: 2026-06-18
Parachute gross up cap: 12500000
Merger consideration per share: 135.11
Nasdaq trading suspension date: 2026-09-04

Price after filing

1 day: 0.0%

Close on the filing date to close N calendar days later (from $135.07). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.